RU2018128793A3 - - Google Patents

Download PDF

Info

Publication number
RU2018128793A3
RU2018128793A3 RU2018128793A RU2018128793A RU2018128793A3 RU 2018128793 A3 RU2018128793 A3 RU 2018128793A3 RU 2018128793 A RU2018128793 A RU 2018128793A RU 2018128793 A RU2018128793 A RU 2018128793A RU 2018128793 A3 RU2018128793 A3 RU 2018128793A3
Authority
RU
Russia
Application number
RU2018128793A
Other languages
Russian (ru)
Other versions
RU2018128793A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018128793A publication Critical patent/RU2018128793A/ru
Publication of RU2018128793A3 publication Critical patent/RU2018128793A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018128793A 2016-01-11 2017-01-10 Способы и составы для лечения и/или защиты от острой печеночной недостаточности и других гепатотоксических состояний RU2018128793A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277232P 2016-01-11 2016-01-11
US62/277,232 2016-01-11
US201662361605P 2016-07-13 2016-07-13
US62/361,605 2016-07-13
PCT/IB2017/050115 WO2017122120A1 (en) 2016-01-11 2017-01-10 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Publications (2)

Publication Number Publication Date
RU2018128793A RU2018128793A (ru) 2020-02-13
RU2018128793A3 true RU2018128793A3 (enExample) 2020-05-25

Family

ID=57909814

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018128793A RU2018128793A (ru) 2016-01-11 2017-01-10 Способы и составы для лечения и/или защиты от острой печеночной недостаточности и других гепатотоксических состояний

Country Status (8)

Country Link
US (2) US11260060B2 (enExample)
EP (2) EP3402475B1 (enExample)
JP (2) JP7311267B2 (enExample)
CN (1) CN108601757A (enExample)
AU (1) AU2017208123B2 (enExample)
CA (1) CA3010915C (enExample)
RU (1) RU2018128793A (enExample)
WO (1) WO2017122120A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260060B2 (en) * 2016-01-11 2022-03-01 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
RU2693677C1 (ru) * 2018-10-15 2019-07-03 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ гемокоррекции при лечении печеночной недостаточности
US20220211780A1 (en) * 2019-05-21 2022-07-07 Pendulum Therapeutics, Inc. Methods And Compositions For Treating Liver Disorders
WO2022269026A1 (en) 2021-06-25 2022-12-29 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Treating acetaminophen overdose
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
US20090234011A1 (en) 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
AU2007308742A1 (en) 2006-10-23 2008-05-02 The Mental Health Research Institute Of Victoria Combination therapy
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
RU2563825C2 (ru) 2009-07-06 2015-09-20 Пледфарма Аб Фармацевтические композиции и терапевтические способы, в которых применяется комбинация комплексного соединения марганца и соединения в форме, не являющейся марганцевым комплексом
CN107353313B (zh) * 2012-01-05 2019-04-09 普莱制药公司 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
US20140178358A1 (en) * 2012-12-21 2014-06-26 The United States of America as represented by the Secretary of Department of Health and Human Servi Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker
US11260060B2 (en) 2016-01-11 2022-03-01 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Also Published As

Publication number Publication date
JP2022019973A (ja) 2022-01-27
US12303516B2 (en) 2025-05-20
US20190015424A1 (en) 2019-01-17
JP2019501226A (ja) 2019-01-17
EP3402475A1 (en) 2018-11-21
US20220133739A1 (en) 2022-05-05
JP7311267B2 (ja) 2023-07-19
CN108601757A (zh) 2018-09-28
AU2017208123B2 (en) 2022-04-21
JP7374163B2 (ja) 2023-11-06
US11260060B2 (en) 2022-03-01
WO2017122120A1 (en) 2017-07-20
CA3010915C (en) 2024-06-04
EP3842040A1 (en) 2021-06-30
EP3842040B1 (en) 2022-03-09
EP3402475B1 (en) 2021-10-20
AU2017208123A1 (en) 2018-07-19
RU2018128793A (ru) 2020-02-13
CA3010915A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CH714036A1 (enExample)
BR122021026889A2 (enExample)
BR112019009201A2 (enExample)
BR112019008128A2 (enExample)
RU2018128793A3 (enExample)
BR112018004348A2 (enExample)
BR112019000781A2 (enExample)
BR112019009262A2 (enExample)
BR112019008107A2 (enExample)
BR202016030146U2 (enExample)
BR102016018018A2 (enExample)
CN303696276S (enExample)
CN303573565S (enExample)
CN303535619S (enExample)
CN303536110S (enExample)
CN303536210S (enExample)
CN303536212S (enExample)
CN303536215S (enExample)
CN303536233S (enExample)
CN303536278S (enExample)
CN303536360S (enExample)
CN303536629S (enExample)
CN303536482S (enExample)
CN303584020S (enExample)
CN303536548S (enExample)

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant